Tag: BIO HEA MTC PHA

Europe Single-use Bioreactors Market to Reach $3.34 Billion by 2032, Growing at a CAGR of 15.3% from 2025, Says Meticulous Research®

Market Growth Driven by Rapid Disposable Technology Adoption, Expanding Biopharmaceutical Sector, and Government Support for Bioproduction REDDING, Calif., June 30, 2025 /PRNewswire/ --According to a...

Europe Single-use Bioreactors Market to Reach $3.34 Billion by 2032, Growing at a CAGR of 15.3% from 2025, Says Meticulous Research®

Market Growth Driven by Rapid Disposable Technology Adoption, Expanding Biopharmaceutical Sector, and Government Support for Bioproduction REDDING, Calif., June 30, 2025 /PRNewswire/ --According to a...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 22, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development...

Clover Initiates Phase I Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates

-- Potential First-in-Class Respiratory Combination Vaccine Candidates SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) Enter the Clinical Trial Stage -- SHANGHAI, June...

Pharmaceutical Industry Calls on G7 to Prioritize Innovation as Strategic Pillar for Health, Growth and Security

GENEVA and OTTAWA, ON, June 12, 2025 /CNW/ - Ahead of the upcoming G7 Leaders' Summit, the global pharmaceutical industry, represented by the International...

ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028

LAUSANNE, Switzerland, June 12, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug...

Results from Phase 1/2 Study of Kelun-Biotech’s TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) in Patients with Unresectable Locally Advanced or Metastatic Solid Tumors Refractory to...

CHENGDU, China, June 10, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that results from the Phase 1/2 study (KL264-01/MK-2870-001)...

Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer

Target Action (PDUFA) Date set for October 7, 2025 Application based on data from IMforte, the first Phase 3 trial demonstrating statistically significant and clinically...

Highlights in Oral Presentation of Mabwell’s 9MW2821 at 2025 ASCO

SHANGHAI, June 5, 2025 /PRNewswire/ -- At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, USA, from May 30 to...

Myanmar Construction Industry Report 2025 | Output to Register an AAGR of 3.9% During 2026-2029, Supported by Investments in Renewable Energy, Infrastructure Projects, and...

Middlefield Canadian Income PCC – Dividend Declaration

Vistra appoints Kim Jenkins as Group Chief Executive Officer

Tag: BIO HEA MTC PHA

Europe Single-use Bioreactors Market to Reach $3.34 Billion by 2032, Growing at a CAGR of 15.3% from 2025, Says Meticulous Research®

Europe Single-use Bioreactors Market to Reach $3.34 Billion by 2032, Growing at a CAGR of 15.3% from 2025, Says Meticulous Research®

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers

Clover Initiates Phase I Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates

Pharmaceutical Industry Calls on G7 to Prioritize Innovation as Strategic Pillar for Health, Growth and Security

ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028

Results from Phase 1/2 Study of Kelun-Biotech’s TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) in Patients with Unresectable Locally Advanced or Metastatic Solid Tumors Refractory to...

Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer

Highlights in Oral Presentation of Mabwell’s 9MW2821 at 2025 ASCO

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us